Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Clin Transl Oncol ; 21(4): 467-478, 2019 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-30298467

RESUMO

AIM: To define recommendations that permit safe management of antineoplastic medication, minimise medication errors and improve the safety of cancer patients undergoing treatment. METHODS: By reviewing the literature and consulting the websites of various health organisations and agencies, an expert committee from the Spanish Society of Hospital Pharmacy and the Spanish Society of Medical Oncology defined a set of safe practices covering all stages of providing cancer therapy to patients. The Spanish Society of Oncology Nursing revised and endorsed the final list. RESULTS: In total, 68 recommendations arranged in five sections were defined. They include issues concerning the training of health professionals, the technological resources needed, treatment planning, informing the patient and his/her family, the processes of prescribing, preparing, dispensing and administering cancer therapy (orally, parenterally or intrathecally), assessing patient adherence and treatment toxicity. CONCLUSIONS: It is essential for healthcare establishments to implement specific measures designed to prevent medication errors, in order to ensure the safety of cancer patients treated with antineoplastic medication.


Assuntos
Antineoplásicos/uso terapêutico , Oncologia/normas , Conduta do Tratamento Medicamentoso/normas , Segurança do Paciente/normas , Antineoplásicos/efeitos adversos , Humanos , Oncologia/organização & administração , Erros de Medicação/prevenção & controle , Neoplasias/tratamento farmacológico , Enfermagem Oncológica/organização & administração , Serviço de Farmácia Hospitalar/organização & administração , Espanha
2.
Proc Natl Acad Sci U S A ; 102(27): 9583-8, 2005 Jul 05.
Artigo em Inglês | MEDLINE | ID: mdl-15983379

RESUMO

Adenosine deaminase (ADA), a protein whose deficit leads to severe combined immunodeficiency, binds to the cell surface by means of either CD26, A(1) adenosine receptors, or A(2B) adenosine receptors. The physiological role of these interactions is not well understood. Our results show that by a 3-fold reduction in the EC(50) for the antigen, ADA potentiated T cell proliferation in autologous cocultures with antigen-pulsed immature or mature dendritic cells. Costimulation was not due to the enzymatic activity but to the interaction of ADA-CD26 complexes in T cells with an ADA-anchoring protein in dendritic cells. From colocalization studies, it is deduced that ADA colocalizing with adenosine receptors on dendritic cells interact with CD26 expressed on lymphocytes. This costimulatory signal in the immunological synapse leads to a marked increase (3- to 34-fold) in the production of the T helper 1 and proimmflamatory cytokines IFN-gamma, TNF-alpha, and IL-6.


Assuntos
Adenosina Desaminase/metabolismo , Células Dendríticas/imunologia , Dipeptidil Peptidase 4/metabolismo , Glicoproteínas/metabolismo , Receptores Purinérgicos P1/metabolismo , Transdução de Sinais/imunologia , Linfócitos T/metabolismo , Adenosina Desaminase/imunologia , Anticorpos Monoclonais/imunologia , Primers do DNA , Dipeptidil Peptidase 4/imunologia , Citometria de Fluxo , Glicoproteínas/imunologia , Humanos , Interferon gama/metabolismo , Interleucina-1/metabolismo , Interleucina-6/metabolismo , Microscopia Confocal , Receptores Purinérgicos P1/imunologia , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Linfócitos T/imunologia , Fator de Necrose Tumoral alfa/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA